APH1105 / Aphios - LARVOL DELTA

Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications. (PubMed, Pharmaceutics) - "Currently, no drugs for intranasal administration in ATD have marketing approval, with only three candidates, insulin, rivastigmine and APH-1105, being clinically investigated. Further studies with different candidates will eventually confirm the potential of the intranasal route of administration in the treatment of ATD."

Journal • Review • Alzheimer's Disease • CNS Disorders • Dementia

Study of APH-1105 in Patients With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - P2; N=60; Not yet recruiting; Sponsor: Aphios; Trial completion date: Dec 2022 ➔ Dec 2024; Trial primary completion date: Sep 2022 ➔ Sep 2024

Clinical • Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • MRI